Amneal Pharmaceuticals, Inc. (AMRX)
Pharmaceutical Preparations · market cap $6.1B · as of 2026-07-13
Research and calibrated estimates, not financial advice — verify before acting.
No upcoming catalysts in our calendar.
| Asset | Phase | Indication |
|---|---|---|
| Phenazopyridine Hydrochloride Tables, USP | Phase 3 | Uncomplicated Urinary Tract Infections |
| Testosterone Topical Gel, Metered Pump | Phase 3 | Primary Hypogonadism |
| Estradiol Vaginal | Phase 3 | Atrophic Vaginitis Due to Menopause |
| Asenapine Sublingual | Phase 3 | Schizophrenia |
| Imatinib Mesylate | Phase 3 | Chronic Myeloid Leukemia |
| Phenazopyridine Hydrochloride | Phase 3 | Pain |
| Test - Bimatoprost Ophthalmic | Phase 3 | Glaucoma, Open-Angle |
| Diclofenac Sodium Topical | Phase 3 | Osteoarthritis |
| Mometasone Furoate Nasal | Phase 3 | Seasonal Allergic Rhinitis |
Daily closes through 2026-11-19. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
- SEC filings — EDGAR filings for AMRX (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 9 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.
